{
    "hands_on_practices": [
        {
            "introduction": "Effective management of immune-related adverse events (irAEs) begins with a robust and systematic diagnostic approach. When a patient receiving immune checkpoint inhibitor therapy presents with a common symptom like diarrhea, constructing a broad differential diagnosis is paramount. This exercise  challenges you to integrate multiple potential etiologies—including infectious, medication-induced, and inflammatory causes—and prioritize diagnostic tests logically, with a crucial emphasis on ruling out infection before presuming an irAE and initiating immunosuppressive treatment.",
            "id": "4806232",
            "problem": "A $62$-year-old man with metastatic non-small cell lung cancer receiving Programmed Death-$1$ (PD-$1$) blockade with pembrolizumab presents with $7$ days of watery diarrhea, approximately $10$ stools per day, associated with crampy lower abdominal pain and low-grade fever of $38.2^\\circ\\mathrm{C}$. There is no overt blood in the stool. He received his second infusion of pembrolizumab $3$ weeks ago. He completed a course of levofloxacin for community-acquired pneumonia $4$ weeks prior. He returned from a $5$-day trip to Mexico $3$ weeks ago, where he ate street food. He has type $2$ diabetes mellitus; metformin was increased from $500$ mg twice daily to $1{,}000$ mg twice daily $2$ weeks ago. He takes a proton pump inhibitor for gastroesophageal reflux disease. Physical examination shows dry mucous membranes, mild diffuse lower abdominal tenderness without guarding, and no peritoneal signs. Laboratory evaluation reveals serum sodium $132$ mmol/L, creatinine $1.6$ mg/dL (baseline $0.9$ mg/dL), white blood cell count $7.8 \\times 10^3/\\mu\\mathrm{L}$, absolute eosinophil count $0.3 \\times 10^3/\\mu\\mathrm{L}$, C-reactive protein $38$ mg/L. He is hemodynamically stable. \n\nYou are asked to construct a differential diagnosis for his diarrhea that integrates infectious, inflammatory (including immune-related colitis), medication-induced, endocrine, and malignant causes, and to select the most appropriate initial diagnostic testing strategy that prioritizes ruling out life-threatening and common etiologies while efficiently distinguishing immune-related adverse events of therapy. Base your reasoning on fundamental definitions of diarrhea subtypes, the mechanism of action of Programmed Death-$1$ blockade, and standard internal medicine principles for evaluating acute diarrhea with potential travel-related exposure and recent antibiotic use. \n\nWhich of the following testing strategies most appropriately prioritizes the evaluation in this patient?\n\nA. Hold pembrolizumab; obtain stool tests including nucleic acid amplification test or toxin enzyme immunoassay for Clostridioides difficile, multiplex bacterial pathogen panel with Shiga toxin, ova and parasites (Giardia and Entamoeba histolytica), and fecal calprotectin; assess thyroid-stimulating hormone and free thyroxine for endocrine immune-related adverse events; review and hold metformin and proton pump inhibitor; if stool studies are negative or symptoms persist beyond $48$–$72$ hours, perform flexible sigmoidoscopy with biopsies; reserve computed tomography of the abdomen and pelvis for severe pain or suspected complications; consider cytomegalovirus testing if prolonged immunosuppression is instituted.\n\nB. Proceed directly to colonoscopy with full bowel preparation to confirm immune-mediated colitis and start high-dose systemic glucocorticoids immediately; defer stool pathogen testing and add broad-spectrum antibiotics empirically after endoscopy.\n\nC. Prioritize computed tomography of the abdomen and pelvis and magnetic resonance enterography to assess for malignant progression and small bowel involvement; defer stool pathogen testing because immune-mediated colitis is the most likely cause; continue pembrolizumab unless imaging shows obstruction.\n\nD. Test only for Clostridioides difficile given prior antibiotic exposure; start oral vancomycin and continue pembrolizumab; no endoscopic evaluation is necessary even if symptoms persist.\n\nE. Obtain stool osmotic gap and fecal fat quantification to evaluate for medication-induced osmotic diarrhea and exocrine pancreatic insufficiency; if the osmotic gap is elevated, simply reduce metformin dose; infectious testing is unnecessary because travel was more than $2$ weeks ago.",
            "solution": "The problem statement describes a complex clinical scenario requiring a systematic diagnostic approach. The patient is a $62$-year-old man with metastatic non-small cell lung cancer on pembrolizumab, a Programmed Death-$1$ (PD-$1$) inhibitor, who presents with acute inflammatory diarrhea. The core of the task is to formulate a differential diagnosis and select the most appropriate initial diagnostic strategy.\n\nThe patient's presentation has several potential etiologies that must be considered and systematically investigated:\n1.  **Immune-Related Adverse Event (irAE): Checkpoint Inhibitor-Induced Colitis.** This is a frequent and potentially severe irAE. The patient's inflammatory symptoms and timing are consistent with this diagnosis.\n2.  **Infectious Colitis.** This is a critical consideration that must be ruled out before initiating immunosuppression. Key possibilities include *Clostridioides difficile* infection (due to recent antibiotic use), traveler's diarrhea (due to travel history), and other enteric pathogens (risk increased by PPI use).\n3.  **Medication-Induced Diarrhea.** The recent increase in metformin dose is a common cause of diarrhea, though it is typically osmotic and less inflammatory.\n\nThe optimal diagnostic strategy must be safe, efficient, and logical, prioritizing the exclusion of infection before diagnosing an irAE.\n\n**Evaluation of Options**\n\n*   **Option A** presents a systematic, comprehensive, and safe approach. It correctly prioritizes holding the suspect drug (pembrolizumab), performing a broad infectious workup (including C. difficile, bacterial pathogens, and parasites), and using non-invasive markers (fecal calprotectin) to confirm inflammation. It appropriately sequences endoscopy after the infectious workup is negative, reserves imaging for complications, and considers other potential irAEs. This aligns perfectly with clinical guidelines.\n\n*   **Option B** is hazardous. Starting high-dose steroids without ruling out infection, especially C. difficile, is a critical safety error that can lead to fulminant colitis and death.\n\n*   **Option C** incorrectly prioritizes imaging over a direct search for the cause and dangerously recommends continuing the offending drug while deferring the essential infectious workup.\n\n*   **Option D** is too narrow. It correctly considers C. difficile but ignores other plausible and important diagnoses like irAE colitis and other infections. Continuing pembrolizumab and forgoing further evaluation if symptoms persist are both incorrect.\n\n*   **Option E** is misguided. It focuses on non-inflammatory causes, ignoring the clear inflammatory signs (fever, elevated CRP), and incorrectly dismisses the need for an infectious workup.\n\nBased on this analysis, Option A is the only strategy that is safe, logical, comprehensive, and consistent with the standard of care.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Once an irAE is suspected, a precise diagnosis is essential, especially when the presentation is severe and complicated by confounding factors. This case  simulates a life-threatening metabolic emergency where you must differentiate between fulminant autoimmune diabetes induced by checkpoint inhibition and hyperglycemia caused by corticosteroids. Success hinges on applying fundamental principles of endocrinology and interpreting key biomarkers, such as C-peptide and autoantibodies, to uncover the correct pathophysiology and select the life-saving management plan.",
            "id": "4806204",
            "problem": "A patient aged $62$ years with metastatic non-small cell lung carcinoma is receiving programmed cell death protein $1$ (PD-$1$) immune checkpoint inhibitor (ICI) therapy with nivolumab. One week ago, for ICI-associated pneumonitis, she began prednisone $60$ mg daily. She now presents with polyuria, polydipsia, and nausea. Vital signs show mild tachycardia; physical examination reveals signs of dehydration without focal neurological deficits. Laboratory studies show plasma glucose $520$ mg/dL, venous pH $7.26$, bicarbonate $12$ mEq/L, anion gap $24$, and serum beta-hydroxybutyrate positive, consistent with diabetic ketoacidosis (DKA). Glycosylated hemoglobin (HbA$1$c) was $5.6\\%$ one month ago and is now $7.4\\%$. Serum C-peptide measured during hyperglycemia is $0.2$ ng/mL (reference $1.1$–$4.4$ ng/mL), and glutamic acid decarboxylase $65$ (GAD$65$) antibodies are positive at $42$ IU/mL (reference $5$ IU/mL). Islet tyrosine phosphatase (IA-$2$) antibodies are pending.\n\nStarting from fundamental immunologic and endocrine principles—namely, that PD-$1$/cytotoxic T-lymphocyte–associated protein $4$ (CTLA-$4$) pathways enforce peripheral tolerance by restraining effector T-cell activity, that type $1$ diabetes mellitus arises from autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency, that C-peptide reflects endogenous insulin secretion, and that glucocorticoids increase hepatic gluconeogenesis and peripheral insulin resistance causing hyperglycemia without direct beta-cell destruction—determine the most likely etiology of her current metabolic derangement and select the best long-term management plan, including whether and when to continue ICI therapy.\n\nWhich option is most appropriate?\n\nA. Diagnose ICI-induced autoimmune type $1$ diabetes; treat as type $1$ diabetes with lifelong basal–bolus insulin; hold ICI during acute DKA and resume once clinically stable with controlled glucose; avoid corticosteroids for glycemic management; add continuous glucose monitoring, patient education on DKA prevention, and screen for other endocrine immune-related adverse events.\n\nB. Diagnose steroid-induced hyperglycemia; taper prednisone and start metformin; insulin is unnecessary; continue ICI without interruption; autoantibody and C-peptide findings do not alter management.\n\nC. Use high-dose corticosteroids specifically to reverse beta-cell autoimmunity; avoid insulin; permanently discontinue ICI because endocrine immune-related adverse events imply irreversible toxicity.\n\nD. Start a sodium–glucose cotransporter $2$ inhibitor and a sulfonylurea for rapid glucose control; expect resolution after steroid taper; autoantibody testing and C-peptide are not required to guide therapy.\n\nE. Diagnose latent autoimmune diabetes in adults unrelated to ICI; permanently stop ICI; use only a short course of insulin until beta-cell recovery; no additional endocrine screening is needed.",
            "solution": "The central task is to determine the cause of the patient's diabetic ketoacidosis (DKA) and devise a management plan. The patient has two potential causes for hyperglycemia: high-dose prednisone and the PD-1 inhibitor, nivolumab.\n\nThe key to the diagnosis lies in differentiating a state of insulin resistance from a state of absolute insulin deficiency.\n*   **Steroid-induced hyperglycemia** is primarily a state of severe insulin resistance. The pancreatic beta cells are intact and respond by producing large amounts of insulin. This would result in a *normal or high* C-peptide level.\n*   **ICI-induced autoimmune diabetes** is mechanistically equivalent to fulminant type 1 diabetes mellitus (T1DM), where autoimmune T-cells destroy pancreatic beta cells, leading to absolute insulin deficiency. This would result in a *profoundly low* C-peptide level.\n\nThe patient's laboratory results are definitive. The C-peptide level is extremely low ($0.2$ ng/mL) in the face of severe hyperglycemia, confirming absolute insulin deficiency. The positive GAD65 antibodies confirm an autoimmune process directed against the beta cells. The diagnosis is therefore ICI-induced autoimmune diabetes. The high-dose prednisone exacerbated the metabolic decompensation by adding insulin resistance on top of the insulin deficiency, but it is not the root cause.\n\nBased on this diagnosis:\n*   **Treatment:** The patient has permanent beta-cell destruction and requires lifelong insulin therapy, typically with a basal-bolus regimen. Oral agents are ineffective.\n*   **ICI Management:** Standard practice is to hold the ICI for a grade 4 toxicity like DKA. However, because endocrine irAEs can be managed with hormone replacement, the ICI can be safely resumed once the patient is metabolically stable on insulin. Permanently stopping the ICI is generally not indicated and would compromise her cancer treatment.\n*   **Comprehensive Care:** Management should include modern diabetes care tools like continuous glucose monitoring (CGM), extensive patient education, and screening for other potential endocrine irAEs.\n\n**Evaluation of Options**\n*   **A:** This option correctly identifies the etiology as ICI-induced T1DM and outlines the correct management: lifelong insulin, temporary hold and subsequent resumption of the ICI, and comprehensive ancillary care. This is the correct choice.\n*   **B:** This option incorrectly diagnoses steroid-induced hyperglycemia and proposes dangerous management (withholding insulin, continuing ICI during DKA).\n*   **C:** This option proposes harmful management (using more steroids, avoiding insulin) and incorrectly recommends permanent ICI discontinuation.\n*   **D:** This option recommends inappropriate oral agents for T1DM and incorrectly assumes the condition is transient. SGLT2 inhibitors are contraindicated in DKA.\n*   **E:** This option misdiagnoses the condition (LADA has a slower onset), incorrectly absolves the ICI, and proposes incorrect management of both the insulin and the ICI.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Managing patients with irAEs often involves navigating subsequent complications, posing some of the most difficult questions in clinical practice. This problem  places you in a common and high-stakes scenario: a patient being treated for ICI pneumonitis with steroids develops new respiratory symptoms. You must skillfully use clinical data, advanced imaging, and specific biomarkers to distinguish between a flare of the underlying autoimmune pneumonitis and a new opportunistic infection, a distinction that carries profoundly different therapeutic consequences.",
            "id": "4806317",
            "problem": "A patient with metastatic melanoma previously treated with programmed cell death protein 1 (PD-1) blockade develops suspected immune checkpoint inhibitor (ICI) pneumonitis. She received prednisone at $1\\,\\mathrm{mg/kg/day}$ initiated $6$ weeks ago and is now on a taper at $25\\,\\mathrm{mg/day}$. Over $3$ days she develops fever to $38.4\\,^{\\circ}\\mathrm{C}$, nonproductive cough, and exertional dyspnea. Vital signs show heart rate $102\\,\\mathrm{beats/min}$, blood pressure $118/68\\,\\mathrm{mmHg}$, respiratory rate $20\\,\\mathrm{breaths/min}$, and oxygen saturation $92\\%$ on room air. Laboratory values include white blood cell count $8.5 \\times 10^{9}/\\mathrm{L}$ with absolute lymphocyte count $0.5 \\times 10^{9}/\\mathrm{L}$, C-reactive protein (CRP) $160\\,\\mathrm{mg/L}$, and creatinine $0.9\\,\\mathrm{mg/dL}$. She has not been receiving Pneumocystis jirovecii prophylaxis. Chest computed tomography (CT) demonstrates new bilateral, predominantly peripheral and peribronchovascular ground-glass opacities with multifocal consolidations and occasional reversed halo signs; there are no centrilobular tree-in-bud nodules, cavitation, or lobar airspace opacities. Sputum Gram stain is without organisms.\n\nYou are asked to discriminate between an ICI pneumonitis flare and infection, using fundamental definitions of host response and validated biomarkers. Consider the following possible additional findings obtained within $24$ hours of presentation. Which set of findings most strongly supports an ICI pneumonitis flare rather than infection and would most justify escalation of immunosuppression while de-escalating empiric antibacterial therapy?\n\nA. Bronchoscopy with bronchoalveolar lavage (BAL) shows total cell count $180\\,\\mathrm{cells/\\mu L}$ with $35\\%$ lymphocytes, $4\\%$ eosinophils, and $55\\%$ macrophages; bacterial, mycobacterial, fungal, and viral studies from BAL are negative. Serum procalcitonin (PCT) is $0.06\\,\\mathrm{ng/mL}$; serum beta-D-glucan is $60\\,\\mathrm{pg/mL}$; serum Aspergillus galactomannan index is $0.2$.\n\nB. Serum procalcitonin is $3.2\\,\\mathrm{ng/mL}$; white blood cell count is $14.0 \\times 10^{9}/\\mathrm{L}$ with $88\\%$ neutrophils; repeat chest CT shows new right lower lobe lobar consolidation with air bronchograms and centrilobular tree-in-bud nodules; blood cultures grow Streptococcus pneumoniae in $1/2$ bottles.\n\nC. Serum beta-D-glucan is $240\\,\\mathrm{pg/mL}$; lactate dehydrogenase is $480\\,\\mathrm{U/L}$; arterial oxygen tension is $58\\,\\mathrm{mmHg}$ on room air with an alveolar-arterial gradient of $45\\,\\mathrm{mmHg}$; repeat chest CT shows diffuse, bilateral, predominantly perihilar ground-glass opacities with interlobular septal thickening; induced sputum polymerase chain reaction is positive for Pneumocystis jirovecii. Serum procalcitonin is $0.08\\,\\mathrm{ng/mL}$.\n\nD. Serum Aspergillus galactomannan index is $1.3$; chest CT shows multiple nodules with surrounding ground-glass (halo sign) and a new cavitary lesion in the right upper lobe; BAL fungal culture grows Aspergillus fumigatus; serum procalcitonin is $0.4\\,\\mathrm{ng/mL}$.",
            "solution": "The clinical challenge is to distinguish an exacerbation of immune-mediated pneumonitis from an opportunistic infection in a patient on corticosteroids. An ICI pneumonitis flare is a sterile, lymphocyte-driven inflammatory process, whereas an infection is caused by a pathogen. The correct answer will be the set of findings that demonstrates evidence of inflammation in the absence of evidence of infection.\n\n*   **Analysis of Option A:** This option provides a cohesive picture of a non-infectious, inflammatory process. The bronchoalveolar lavage (BAL) shows a lymphocytic alveolitis ($35\\%$ lymphocytes), which is a classic finding in ICI pneumonitis. Crucially, comprehensive microbiological studies of the BAL fluid are negative. Furthermore, key serum biomarkers for infection are all negative: procalcitonin (PCT) is very low, arguing against bacterial infection; beta-D-glucan is negative, arguing against fungal infections like *Pneumocystis*; and *Aspergillus* galactomannan is negative. This combination of findings strongly supports a diagnosis of an ICI pneumonitis flare.\n\n*   **Analysis of Option B:** This option provides definitive evidence of a bacterial infection. The very high PCT, neutrophilic leukocytosis, lobar consolidation on CT, and positive blood culture for *Streptococcus pneumoniae* are all classic signs of bacterial pneumonia and sepsis. This points away from an ICI flare.\n\n*   **Analysis of Option C:** This option provides definitive evidence of *Pneumocystis jirovecii* pneumonia (PJP), a common opportunistic fungal infection in patients on steroids. The high beta-D-glucan, severe hypoxemia, classic CT findings, and positive PCR for *P. jirovecii* confirm the diagnosis of infection.\n\n*   **Analysis of Option D:** This option provides definitive evidence of invasive pulmonary aspergillosis, another opportunistic fungal infection. The high *Aspergillus* galactomannan, classic CT findings (halo sign, cavitation), and positive fungal culture from BAL are diagnostic of this infection.\n\n**Conclusion:** Only Option A presents a scenario where infection is systematically and convincingly ruled out, while findings consistent with an underlying immune-mediated process (lymphocytic alveolitis) are present. Therefore, this is the only set of findings that would justify escalating immunosuppression for a pneumonitis flare.",
            "answer": "$$\n\\boxed{A}\n$$"
        }
    ]
}